Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.
In a day marked by significant market movements, EchoStar's stock skyrocketed following AT&T's $23 billion purchase of wireless licenses. Eli Lilly also saw gains with promising diabetes drug results, while Nvidia's upcoming report looms large.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.
Discover how Eli Lilly's $50 billion investment in US manufacturing will create high-wage jobs, advance pharmaceutical innovation, and boost economic growth.
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
